Orthopaedic Surgery, McMaster University, Hamilton, ON, Canada.
J Shoulder Elbow Surg. 2010 Mar;19(2 Suppl):104-9. doi: 10.1016/j.jse.2009.12.017.
Management of massive, degenerative, and irreparable rotator cuff tears is challenging. Excessive re-tear rates and poor clinical outcome after standard repair have led to alternative methods of treatment. Tendon transfers and shoulder arthroplasty have had mixed results; both are invasive procedures with high potential morbidity. We began performing rotator cuff augmentation and replacement using GraftJacket allograft acellular human dermal matrix as a biologic minimally invasive alternative in this difficult population almost 6 years ago. This article highlights our preferred arthroscopic technique and early results.
From January 2004 to June 2007, 45 patients (36 men, 9 women) with massive rotator cuff tears were treated arthroscopically with the GraftJacket allograft. All patients completed a preoperative University of California, Los Angeles (UCLA) score. Follow-up was a minimum of 2 years (range, 24-68 months) and patients completed UCLA, Western Ontario Rotator Cuff (WORC), and American Shoulder and Elbow Surgeons (ASES) scores.
Analysis was performed using the 3 validated outcomes measurement scores. The mean UCLA score increased from 18.4 preoperatively to 27.5 postoperatively (P < .000). The average WORC score was 75.2, and the ASES score was 84.1 at the final follow-up.
Evidence-based data to outline an algorithm for management of irreparable rotator cuff tears is being developed. We documented significant clinical improvement with arthroscopic rotator cuff reconstruction using the GraftJacket allograft acellular human dermal matrix. The procedure is safe and associated with high patient satisfaction, without the morbidity of tendon transfer or arthroplasty. For those few cases where further surgery is required, no bridges are burned. The early success of this procedure warrants further study with more patients, longer follow-up, and higher levels of evidence-based investigation.
治疗大量、退行性和不可修复的肩袖撕裂是具有挑战性的。标准修复后的过度再撕裂率和不良临床结果导致了替代治疗方法。肌腱转移和肩关节置换术的效果参差不齐;两者都是具有高潜在发病率的侵入性手术。大约 6 年前,我们开始使用 GraftJacket 同种异体脱细胞真皮基质作为一种生物微创替代方法,对这一困难人群进行肩袖增强和置换。本文重点介绍我们首选的关节镜技术和早期结果。
从 2004 年 1 月至 2007 年 6 月,45 例(36 名男性,9 名女性)大量肩袖撕裂患者接受了 GraftJacket 同种异体的关节镜治疗。所有患者均完成了术前加利福尼亚大学洛杉矶分校(UCLA)评分。随访时间至少为 2 年(范围为 24-68 个月),患者完成了 UCLA、安大略西部肩袖(WORC)和美国肩肘外科医生(ASES)评分。
使用 3 种经过验证的结果测量评分进行了分析。UCLA 评分从术前的 18.4 分增加到术后的 27.5 分(P <.000)。WORC 平均得分为 75.2,ASES 评分为 84.1。
正在制定用于不可修复肩袖撕裂管理的循证数据算法。我们通过使用 GraftJacket 同种异体脱细胞真皮基质的关节镜肩袖重建记录了显著的临床改善。该手术安全,患者满意度高,没有肌腱转移或关节置换的发病率。对于少数需要进一步手术的病例,没有留下后遗症。该手术的早期成功需要进一步研究更多的患者、更长的随访时间和更高水平的循证研究。